B
Bone Biologics Corp
BBLGCIK 0001419554NasdaqNon-AcceleratedSmaller ReportingOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-3.11M
Total Assets
$5.80M
Equity
$5.38M
Shares Out
1.80M
Op. Cash Flow
$-2.70M
Business
Bone Biologics Corp is a clinical-stage medical device company focused on bone regeneration for spinal fusion using its recombinant human protein NELL-1. Its primary product candidate is NB1, a NELL-1/DBM (demineralized bone matrix) fusion device sold as a single-dose vial and convenience kit for use with cleared DBM Putty and standard surgical hardware. Key business applications include lumbar spine fusion and broader orthopedic indications such as trauma, non-union fractures and osteoporosis. The company pursues regulatory approval via clinical trials (currently a pilot study in Australia) and intends commercialization through spine surgeons, hospitals and established biologics supply channels globally.
Summary from filing dated 2025-02-26
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | — | — | — | — | — | |
| Research and development | 1 | 2 | 7 | 2 | 82,044 | |
| General and administrative | 2 | 2 | 3 | 2 | 1 | |
| Total operating expenses | 3 | 4 | 9 | 4 | 1 | |
| Loss from operations | −3 | −4 | −9 | −4 | −1 | |
| Change in fair value of warrant liability | 3,967 | 51,081 | 892,693 | 3 | — | |
| Interest income | 121,984 | 55,660 | 1,868 | — | — | |
| Total other income | 125,951 | 106,741 | 479,572 | 2 | −507,609 | |
| Net loss | −3 | −4 | −9 | −1 | −2 | |
| Deemed dividend on warrant inducements | — | −3 | — | — | — | |
| Net loss attributable to common stockholders | −3 | −7 | −9 | — | — | |
| Weighted average shares outstanding - basic | 1 | 252,960 | 263,137 | 47,658 | — | |
| Weighted average shares outstanding - diluted | 1 | 252,960 | 263,137 | 47,658 | — | |
| Loss per share - basic | −2.65 | −28.96 | −34.01 | −31.15 | −0.35 | |
| Loss per share - diluted | −2.65 | −28.96 | −34.01 | −31.15 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 5 | 3 | 3 | 8 | 7 | |
| Advances on research and development contract services | 208,972 | 258,059 | 328,844 | 579,910 | — | |
| Prepaid insurance | 232,946 | 268,179 | 372,350 | 364,536 | — | |
| Interest Receivable | 9,895 | — | — | — | — | |
| Prepaid expenses | 10,000 | 10,000 | 10,000 | 12,479 | — | |
| Total current assets | 6 | 4 | 4 | 8 | — | |
| Total assets | 6 | 4 | 4 | 8 | 7 | |
| Accounts payable and accrued expenses | 417,884 | 373,042 | 360,662 | 104,786 | 99,909 | |
| Warrant liability | 703 | 4,670 | — | — | — | |
| Total current liabilities | 418,587 | 377,712 | 831,402 | 3 | 99,909 | |
| Total liabilities | 418,587 | 377,712 | 831,402 | 3 | 99,909 | |
| Commitments and Contingencies | — | — | — | — | — | |
| Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,795,260 and 492,417 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,795 | 492 | 534 | 64 | 10,350 | |
| Additional paid-in capital | 94 | 89 | 84 | 78 | 77 | |
| Accumulated deficit | −88 | −85 | −81 | −72 | −70 | |
| Total stockholders equity | 5 | 3 | 3 | 6 | 7 | |
| Total liabilities and stockholders equity | 6 | 4 | 4 | 8 | 7 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 256,358 | 188,819 | 152,599 | 266,633 | 207,035 | |
| Advances on research and development contract services | 49,087 | 70,785 | 251,066 | −579,910 | — | |
| Prepaid insurance | 35,233 | 104,171 | — | — | — | |
| Interest receivable | −9,895 | — | — | — | — | |
| Accounts payable and accrued expenses | 91,025 | 89,780 | 255,876 | 4,877 | −365,487 | |
| Accrued legal settlement | — | −414,989 | 414,989 | — | — | |
| Net cash used in operating activities | −3 | −4 | −10 | −4 | −1 | |
| Proceeds from issuance of common shares from ATM, net of costs | 347,549 | 1 | — | — | — | |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | 4 | 2 | 5 | 4 | 7 | |
| Proceeds from issuance of common shares from warrant inducement, net of costs | — | 2 | — | — | — | |
| Exercise of pre-funded warrants | — | 662 | — | — | — | |
| Net cash provided by financing activities | 5 | 4 | 5 | 4 | 8 | |
| Net increase in cash | 2 | 298,562 | −5 | 862,947 | 7 | |
| Income taxes paid | — | — | — | — | — | |
| Options issued to settle accrued bonus | 46,183 | 77,400 | — | — | — | |
| Deemed dividend warrant inducement | — | 3 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro